ArticleEuropean journal of medical research2026
Effects of a high proportion of cefoperazone/tazobactam on lung function and bacterial clearance rate in patients with chronic obstructive pulmonary disease and lower respiratory tract infection Klebsiella pneumoniae.
Article in European journal of medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe aim of this study was to probe the clinical effect of a high proportion of cefoperazone/tazobactam in the treatment of patients with chronic obstructive pulmonary disease (COPD) involuted with lower respiratory tract infection Klebsiella pneumoniae.
methods80 patients with COPD and lower respiratory tract infection Klebsiella pneumoniae accepted to the Respiratory Department of our hospital from January 2022 to January 2024 were selected as the research subjects. They were randomly divided into a low-proportion group (n = 40) and a high-proportion group (n = 40). Patients in the low-proportion group and the high-proportion group received intravenous infusion of cefoperazone/tazobactam in a proportion of 4: 1 and 8: 1 respectively, and both were treated for one week.
resultsAfter one week of treatment, the APACHE Ⅱ scores and dyspnea scores of patients in the high-proportion group and the low-proportion group were significantly lower than those before treatment (P < 0.05), and the low-proportion group was slightly lower than the high-proportion group. After one week of treatment, the serum CRP concentration of patients in the low-proportion group and the high-proportion group was reduced compared with before treatment (P < 0.05), while the lung function FEV1/FVC (%) value was increased compared with before treatment (P < 0.05), and the FEV1/FVC (%) value after treatment was higher in the high-proportion group than in the low-proportion group (P < 0.05).
conclusionIn the treatment of COPD patients with lower respiratory tract infection Klebsiella pneumoniae, intravenous infusion of cefoperazone/tazobactam in a proportion of 8: 1 is a better treatment plan. High-proportion intravenous infusion of cefoperazone/tazobactam can quickly restore the patient's lung function and is more effective in improving treatment efficiency and bacterial clearance rate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.